% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mhlenbruch:301479,
      author       = {L. Mühlenbruch and D. Rieger and H. Becker and A. M.
                      Santos Leite and I. Mäurer and J. Schittenhelm$^*$ and M.
                      Dubbelaar and L. Bichmann and O. Kohlbacher and H.-G.
                      Rammensee$^*$ and C. Gouttefangeas$^*$ and M. Tatagiba$^*$
                      and J. Walz$^*$ and G. Tabatabai$^*$},
      title        = {{T}he immunopeptidomic landscape of ependymomas provides
                      actionable antigens for {T}-cell-based immunotherapy.},
      journal      = {Neuro-oncology advances},
      volume       = {7},
      number       = {1},
      issn         = {2632-2498},
      address      = {Oxford},
      publisher    = {Oxford University Press},
      reportid     = {DKFZ-2025-01021},
      pages        = {vdae226},
      year         = {2025},
      abstract     = {Ependymoma are primary tumors of the nervous system. Due to
                      their growth pattern, many ependymomas can be managed with
                      neurosurgical resection alone. A substantial proportion of
                      these tumors recurs or displays infiltrative growth
                      patterns. Further established therapeutic options include
                      radiation therapy. Systemic treatment options include
                      platinum-based therapeutic regimes or a combination of
                      lapatinib and temozolomide. Peptide-based immunotherapy
                      represents a promising therapeutic strategy relying on the
                      induction of tumor-specific T cells targeting human
                      leukocyte antigens (HLA)-presented peptides. Our work aimed
                      to analyze the landscape of naturally presented HLA class I
                      and II ligands of primary ependymomas (EPN) to delineate
                      EPN-associated antigens.We investigated 22 EPN tissue
                      samples using a comparative mass spectrometry-based
                      immunopeptidomic approach. Additionally, EPN-specific
                      antigens were functionally characterized in T-cell-based
                      immunogenicity assays.We discovered a subset of
                      EPN-exclusive peptides including HLA-A*02 and
                      HLA-A*25/HLA-A*26-restricted HLA ligands and identified a
                      small panel of cancer/testis antigens (CTAs)-derived HLA
                      ligands. Furthermore, we outlined immunopeptidomic
                      alterations in different ependymoma subgroups and
                      progressive ependymoma. Subsequently, we performed
                      functional characterization of the previously identified
                      HLA-A*02:01 restricted peptide FLDS to demonstrate
                      immunogenicity in vitro.The immunopeptidome landscape of
                      EPNs provides actionable targets that could further be
                      explored as a T cell-based immunotherapeutic strategy in
                      this tumor entity.},
      keywords     = {HLA ligands (Other) / cancer vaccination (Other) /
                      immunotherapy (Other) / mass spectrometry (Other) / peptide
                      vaccine (Other)},
      cin          = {TU01},
      ddc          = {610},
      cid          = {I:(DE-He78)TU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40376681},
      pmc          = {pmc:PMC12080555},
      doi          = {10.1093/noajnl/vdae226},
      url          = {https://inrepo02.dkfz.de/record/301479},
}